May 13, 2024 06:00 AM Eastern Daylight Time

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Download

Small JPEG, 191x36, 8.2 KB
Preview JPEG, 144x27, 5.2 KB
Thumbnail JPEG, 120x23, 3.9 KB

Smart Multimedia Gallery

http://www.businesswire.com/multimedia/syndication/20240510475155/en/5648447/AC-Immune-and-Takeda-Sign-Exclusive-Option-and-License-Agreement-for-Active-Immunotherapy-Targeting-Amyloid-Beta-for-Alzheimer%E2%80%99s-Disease

View and Share Logo

http://www.businesswire.com/multimedia/syndication/20240510475155/en/5648448/AC-Immune-and-Takeda-Sign-Exclusive-Option-and-License-Agreement-for-Active-Immunotherapy-Targeting-Amyloid-Beta-for-Alzheimer%E2%80%99s-Disease

Share

Email

All News | News with Multimedia > Press Release: AC Immune and Takeda Sign Exclusive Option and ...

Get Business Wire News on Your Website

Terms of Use | © 2024 Business Wire